BioSpace News Archive

DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Tuesday, February 25 at 8:30 a.m. ET to discuss the Company’s fourth quarter and full-year 2019 financial results and corp

Conference Call Scheduled for Wednesday, February 26 at 4:30 p.m. Eastern Time

CRANBURY, N.J. , Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled

Feb. 19, 2020 12:30 UTC AlloVir to Present at the SVB Leerink 9 th Annual Global Healthcare Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City. AlloVir, an ElevateBio portfolio company, is the leader in the

Feb. 19, 2020 12:30 UTC -- Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors -- -- Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital , and Dolby Ventures -- CAMBRIDGE, Mass.--( BUSINESS WIRE )-- EnClear Therapies , a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today anno

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that John Lubniewski, President and CEO, will present a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference,

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that the company’s therapeutic Immuno-STAT™

CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC).